The latest price target for T2 Biosystems (NASDAQ:TTOO) was reported by Canaccord Genuity on July 30, 2024. The analyst firm set a price target for $5.00 expecting TTOO to rise to within 12 months (a possible 839.85% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for T2 Biosystems (NASDAQ:TTOO) was provided by Canaccord Genuity, and T2 Biosystems maintained their hold rating.

The last upgrade for T2 Biosystems Inc happened on February 18, 2022 when Alliance Global Partners raised their price target to $0.7. Alliance Global Partners previously had a neutral for T2 Biosystems Inc.

The last downgrade for T2 Biosystems Inc happened on October 14, 2022 when Canaccord Genuity changed their price target from $12.5 to $2.5 for T2 Biosystems Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of T2 Biosystems, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for T2 Biosystems was filed on July 30, 2024 so you should expect the next rating to be made available sometime around July 30, 2025.

While ratings are subjective and will change, the latest T2 Biosystems (TTOO) rating was a maintained with a price target of $3.00 to $5.00. The current price T2 Biosystems (TTOO) is trading at is $0.53, which is out of the analyst’s predicted range.